STORM Therapeutics raises $56M Series C and doses first patient in Phase 2 sarcoma trial of STC-15, the world’s first RNA ...
The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indicationsFirst‑in‑class METTL3 inhibitor reprograms ...
First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients ...
STORM Therapeutics, a Cambridge-based clinical stage company targeting RNA modifications to reprogram cells and develop novel ...
Eli Lilly and peers like Novartis fuel a 2026 pharma M&A surge, striking billion-dollar deals to expand pipelines, tap AI innovation, and counter patent pressures.
Storm Therapeutics raises $56M in Series C funding to accelerate cancer therapy development and expand its innovative ...
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the publication of data from the ongoing Phase 1/2 BEACON ...
This important paper substantially advances our understanding of how Molidustat may work, beyond its canonical role, by identifying its therapeutic targets in cancer. This study presents a compelling ...
Building on validated HIP technology, Sana Biotechnology is advancing SC451, a stem cell-derived therapy designed as a one-time treatment targeting normal blood glucose without exogenous insulin or ...
Laura Nicholson, 45, wants to raise awareness about the premenstrual condition PMDD, which causes extreme psychological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results